| Literature DB >> 35309167 |
Afshan Hassan1, Devendra Prasad1, Shalli Rani1, Musah Alhassan2.
Abstract
While the world continues to grapple with the devastating effects of the SARS-nCoV-2 virus, different scientific groups, including researchers from different parts of the world, are trying to collaborate to discover solutions to prevent the spread of the COVID-19 virus permanently. Henceforth, the current study envisions the analysis of predictive models that employ machine learning techniques and mathematical modeling to mitigate the spread of COVID-19. A systematic literature review (SLR) has been conducted, wherein a search into different databases, viz., PubMed and IEEE Explore, fetched 1178 records initially. From an initial of 1178 records, only 50 articles were analyzed completely. Around (64%) of the studies employed data-driven mathematical models, whereas only (26%) used machine learning models. Hybrid and ARIMA models constituted about (5%) and (3%) of the selected articles. Various Quality Evaluation Metrics (QEM), including accuracy, precision, specificity, sensitivity, Brier-score, F1-score, RMSE, AUC, and prediction and validation cohort, were used to gauge the effectiveness of the studied models. The study also considered the impact of Pfizer-BioNTech (BNT162b2), AstraZeneca (ChAd0x1), and Moderna (mRNA-1273) on Beta (B.1.1.7) and Delta (B.1.617.2) viral variants and the impact of administering booster doses given the evolution of viral variants of the virus.Entities:
Mesh:
Year: 2022 PMID: 35309167 PMCID: PMC8931177 DOI: 10.1155/2022/7731618
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Dynamics of transmission for the spread of SARS-Covid-19.
Figure 2Graph depicting vaccination rates by region for SARS-COVID-19 [17].
Figure 3SARS-COVID-19 cases per capita in different parts of the world from 28 February 2020 to 30 October 2021 [17].
Description of SARS-COVID-19 mutant strains [7].
| Variants of interest | |||
|---|---|---|---|
| S. no. | WHO label | Lineage | First documented sample |
| 1 | Epsilon | B.1.427/B.1.429 | U.S.A., March 2020 |
| 2 | Zeta | P.2 | Brazil, April2020 |
| 3 | Eta | B.1.525 | Multiple, Dec 2020 |
| 4 | Theta | P.3 | Philippines, January 2021 |
| 5 | Iota | B.1.526 | U.S.A., Nov 2020 |
| 6 | Kappa | B.1.617.1 | India, October 2020 |
| 7 | Lambda | C.37 | Peru, August 2020 |
| Variants of concern | |||
| 1 | Alpha | B.1.1.7 | U.K., September 2020 |
| 2 | Beta | B.1.351 | South Africa, May 2020 |
| 3 | Gamma | P.1 | Brazil, November 2020 |
| 4 | Delta | B.1.617.2 | India, October 2002 |
| 5 | Omicron | B.1.1.529 | South Africa, November 2021 |
| Variants of high consequence (none identified) | |||
Figure 4Map depicting the known locations of cumulative reported SARS-COVID-19 cases [17].
Figure 5Testing techniques for detection of SARS-COVID-19 [8].
Categories of vaccines for SARS-COVID-19 [9].
| Vaccine category | Type/company | No. of doses | Other vaccines employing this technology | Storage |
|---|---|---|---|---|
| RNA | Pfizer-BioNTech | 2 | No other licensed vaccines | Pfizer-BioNTech: -70°C and 2-8°C for up to 5 days |
| Viral vector | Oxford-AstraZeneca | 1-2 | Ebola | 2-8°C |
| Whole virus | Sinovac (inactivated) | 2 | Whooping cough (inactivated) | 2-8°C |
| Sinopham (inactivated) | HIPV/cervical cancer (virus-like-particle) | |||
| Protein subunit | Novavax | 2 | Hepatitis B | 2-8°C |
Figure 6Framework depicting different phases employed for current SLR on SARS-COVID-19 [31].
Figure 7Flowchart depicting PRISMA-based stepwise methodology for the development of review protocol for current SLR [31].
Figure 8Flowchart depicting identified databases and evaluation criteria for final selection of articles for current SLR on SARS-COVID-19 [31].
Quality evaluation questions for assessing the quality of selected articles.
| Quality evaluation ID | Quality evaluation questions |
|---|---|
| QE1 | Is there a clear articulation of the objectives of the undertaken research? |
| QE2 | Are the predicted models justifiable and deliberate under a given context or setting? |
| QE3 | Are the findings deliberated by the prediction models validated? |
| QE4 | Are sufficient datasets employed for experimental setup? |
| QE5 | Are the predicted models compared with others to ensure efficiency? |
| QE6 | Does the study narrate its limitations? |
| QE7 | Do the prediction models motivate academia to continue the chosen research path? |
| QE8 | Is the accuracy of the predicted model(s) reported? |
Quality assessment scores for selected articles.
| Article Id | Author | QE1 | QE2 | QE3 | QE4 | QE5 | QE6 | QE7 | QE8 | Total score |
|---|---|---|---|---|---|---|---|---|---|---|
| A1 | Wu and McGoogan et al. [ | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0 | 5 |
| A2 | Bottcher et al. [ | 1 | 0.5 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 5.5 |
| A3 | Wu et al. [ | 1 | 0.5 | 1 | 0 | 0 | 1 | 1 | 0.5 | 5 |
| A4 | Read et al. [ | 1 | 0.5 | 1 | 0 | 0 | 1 | 1 | 0.5 | 5 |
| A5 | Hong et al. [ | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 6 |
| A6 | Zhong et al. [ | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0.5 | 4.5 |
| A7 | Hassanein et al. [ | 1 | 0.5 | 1 | 0 | 0 | 1 | 0.5 | 1 | 5 |
| A8 | De Moraes et al. [ | 1 | 1 | 0.5 | 0 | 1 | 1 | 0.5 | 1 | 6 |
| A9 | Zoabi et al. [ | 1 | 1 | 0.5 | 0 | 1 | 1 | 0.5 | 1 | 6 |
| A10 | Farooq and Bazaz [ | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 6 |
| A11 | Dos Santos Santana et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 |
| A12 | Gupta [ | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0 | 4.5 |
| A13 | Anderez et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 6.5 |
| A14 | Goodman-Meza et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| A15 | Ndaïrou et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 6 |
| A16 | Kyrychko et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 6.5 |
| A17 | Lourenço et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 6.5 |
| A18 | Tomochi and Kono [ | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 5.5 |
| A19 | Khan et al. [ | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6.5 |
| A20 | Hassan et al. [ | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| A21 | Anastassopoulou et.al [ | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 6.5 |
| A22 | Saxena et al. [ | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 6.5 |
| A23 | Mandal et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 6.5 |
| A24 | Saikia et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| A25 | Hassen et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 6 |
| A26 | Nguemdjoid et al. [ | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| A27 | Munoz-Fernandez et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| A28 | Grimm et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 |
| A29 | Fengid et al. [ | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6.5 |
| A30 | Sharpio et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| A31 | Malavika et al. [ | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6.5 |
| A32 | Rahimi et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 7.5 |
| A33 | Gecili et al. [ | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 6.5 |
| A34 | Alshomrani et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 6.5 |
| A35 | Chen et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| A36 | Ala'raj et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 7.5 |
| A37 | Peng et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 6 |
| A38 | Shin [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| A39 | Li et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| A40 | De La Sen et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| A41 | Abbasi et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 6 |
| A42 | Khanday et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 5.5 |
| A43 | Mojjada et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| A44 | Sen and Sen [ | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 6.5 |
| A45 | Goo et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 0.5 | 1 | 5.5 |
| A46 | Lopez et al. [ | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 6.5 |
| A47 | Tang et al. [ | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 6.5 |
| A48 | Lopez et al. [ | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7.5 |
| A49 | Pouwels et al. [ | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 7 |
| A50 | Mlochova et al. [ | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 6.5 |
Figure 9Chart illustrating percentage-wise model-type used for SARS-COVID-19.
Figure 10Graph depicting the type of machine-learning techniques used for SARS-COVID-19.
Types of models employed for modelling SARS-COVID-19.
| Author/reference | Major contribution | Type of model employed |
|---|---|---|
| Wu and McGoogan et al. [ | Estimation of case fatality ratio (CFR) to assess the severity of COVID-19 for China. | Basic SIR model |
| Bottcher et al. [ | Evaluation of factors influencing the population-based CFR's and individual-based CFR's at a constant recovery and death rate for China. | SIR model |
| Wu et al. [ | Deduction of reproductive ratio, R0, to be roughly equal to 2.7 for Wuhan, China. | SIER model |
| Read et al. [ | Early estimation of various parameters concerning epidemiology and predicts the value of the reproductive ratio, R0, to be 3.1 for China. | SIR model |
| Hong et al. [ | Evaluating the value of R0 to enhance the effectiveness of various policies for early control of the pandemic for China. | SIR model |
| Zhong et al. [ | Modeling the infection and removal rates of COVID-19 and prediction of the cumulative COVID-19 cases for China | SIR model |
| Hassanein et al. [ | Detection of the presence of COVID-19 infection in the lungs at early stages. | SVM |
| De Moraes et al. [ | Employing machine learning algorithms to prioritize the infected cases for receiving the RT-PCR (reverse transcription polymerase chain reaction) tests in case of limited testing resources. | Machine learning models: SVM, RF, GBT, and LR models |
| Zoabi et al. [ | Prioritizing the infected cases for receiving the RT-PCR (reverse transcription polymerase chain reaction) in case of limited testing resources. | DT |
| Farooq et al. [ | Understanding the trend of infectious spread for the worst-hit states of India. | SIR model |
| Dos Santos Santana et al. [ | Prioritization of the infected cases for receiving the RT-PCR (reverse transcription polymerase chain reaction) tests in case of limited testing resources. | Machine learning models: SVM, RF, GBT, LR, and DT models |
| Gupta et al. [ | Computation of reproductive ratio, R0, to predict the future trend of COVID-19 for three weeks' time. | SIER |
| Anderez et al. [ | Modeling the mortality rate for people who are already vulnerable to infection due to their advanced age or existing combordities before getting exposed to the virus. | SIER |
| Goodman-Meza et al. [ | Various features and different clinical diagnoses like complete blood counts (CBC's) and various inflammatory markers are studied to diagnose a person as being COVID-19 positive or negative. | Machine learning and ensemble models: SVM, LR, RF, AdaBosst, and XGBoost |
| Ndaïrou et al. [ | Graphing the number of confirmed, recovered, and fatality cases using a dataset within a stipulated time period. | SIR model |
| Kyrychko et al. [ | Exploration of the impact of lockdown strategies on infection and death rates. | SIER |
| Lourenço et al. [ | Study the severity spread of COVID-19 via modeling of infections. | SIR model |
| Tomochi and Kono [ | Modeling different parameters associated with COVID-19, viz., incubation period, reproductive number, effective reproductive number, the peak of infection, and herd immunity threshold. | SIIR model: incorporation of I compartment for modeling asymptomatic infections |
| Khan et al. [ | Impact of lockdown strategies on infection and death rates. | SIER |
| Hassan et al. [ | The study explores the impact of lockdown strategies on infection, recovery, and death rates. | SIRD model |
| Anastassopoulou et al. [ | Modeling the effect of various parameters, viz., CFR (case fatality ratio), R0 (reproductive ratio) related to COVID-19 epidemiology on the infection, death, and recovery rates. | SIRD |
| Saxena et al. [ | Study various parameters related to COVID-19 transmission, viz., contact rate, reproductive rate (R0), and range of COVID-19 spread. | SIER |
| Mandal et al. [ | Prediction of the infection rates for three regions of India. | SIER |
| Saikia et al. [ | Study the effect of asymptomatic infections on the transmission rate of the COVID-19. | SIER |
| Hassen et al. [ | Modeling the different epidemiological parameters, viz., transmission rate and reproductive rate (R0) for COVID-19. | SIR |
| Nguemdjoid et al. [ | Study the effect of various intervention measures on the pandemic's reproductive rate (R0) to flatten the curve of COVID-19. | SIR |
| Munoz-Fernandez et al. [ | Study of the daily infections, transmission rates, and deaths due to COVID-19. | SIR |
| Grimm et al. [ | Modeling the effect of various intervention measures on the mitigation of COVID-19 spread. | SEIR |
| Fengid et al. [ | Prediction of infection and mortality rates. | SEIR |
| Sharpio et al. [ | Estimation of the infection rates and reproductive rates (R0) of epidemic. | SIR model |
| Malavika et al. [ | Prediction of the maximum number of active cases and study the effect of three-week lockdown and other intervention measures on the curve of COVID-19. | Logistic growth curve model and time interrupted regression model |
| Rahimi et al. [ | Prediction of infection rates, reproductive rates, total confirmed and death cases. | Hybrid: SEIR and SVM |
| Gecili et al. [ | Modeling the number of confirmed positive, recovery, and death cases for COVID-19. | Holt model, ARIMA, TBATS, cubic smoothing spline model |
| Alshomrani et al. [ | Estimating various epidemiological parameters, viz., reproductive rate, transmission rate, and recovery rate by fitting the parameters. | SIR model |
| Chen et al. [ | Study the effect of asymptomatic individuals on the spread of COVID-19. | SEIR |
| Ala'raj et al. [ | Study the cumulative number of infectives, recovery, and death cases due to COVID-19. | SEIR with ARIMA corrections |
| Peng et al. [ | Study the unreported infection rate (UFR), infection fatality rate (IFR), and transmission rate (TR) for COVID-19 cases. | SIR |
| Shin [ | Modeling through multistage transitions to understand the dynamics of three successive waves of COVID-19 transmission. | SEIR |
| Li et al. [ | Modeling various disease-related parameters, viz., reproductive rate, incubation period, transmission rate (TR), and time to hospitalization (TSOH). | SEIR |
| De La Sen et al. [ | Study the effect of partial and total quarantine of both infectious and susceptible populations without the inclusion of demography and mortality on the transmission rate of COVID-19. | SIR |
| Abbasi et al. [ | Study the effect of quarantine on the infection and recovery rates of COVID-19. | SQEIAR |
| Khanday et al. [ | Prediction of the number of infected COVID-19 cases-recovered and death cases. | Machine learning and regression models: SVM, ES, LR, and LASSO |
| Mojjada et al. [ | Modeling the infection and deaths for COVID-19 spread. | SIR, RF |
| Sen and Sen [ | Modeling the dynamics of COVID-19 transmission in terms of infection rates. | SIR |
| Goo et al. [ | Prediction of the number of future infections and mortality rates due to COVID-19. | Hybrid: SEIR, Poisson model, GBA, linear local regression, and negative binomial (NB) |
| Bernal et al. [ | Study the effect of Pfizer-BioNTech and Oxford-AstraZeneca on infection, mortality, and alpha (B.1.1.7) variant. | Experimental case study |
| Tang et al. [ | Study the effect of Moderna and Pfizer-BioNTech on infection, mortality, and delta (B.1.617.2) variant. | Case study |
| Bernal et al. [ | Study the effect of Pfizer-BioNTech and Oxford-AstraZeneca on alpha (B.1.1.7) variant and delta (B.1.617.2) COVID-19 variant. | Experimental case study |
| Pouwels et al. [ | Study the effect of Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna on delta (B.1.617.2) COVID-19 variant. | Experimental case study |
| Mlcochova et al. [ | Study the effect of Moderna and Oxford-AstraZeneca on infection, mortality, alpha (B.1.1.7), and delta (B.1.617.2) variant. | Bayesian model |
Figure 11Graph portraying dynamics of predictions for SARS-COVID-19.
Quality Evaluation Metrics used by the selected articles.
| Article Id | Model/algorithm | Reported Quality Evaluation Metric (QEM) |
|---|---|---|
| A1 | Basic SIR model | CFR = 2.4, training cohort = 0.834, validation cohort = 0.804 |
| A2 | SIR model | CFR = 4.6, training cohort = 0.91, validation cohort = 0.86 |
| A3 | SIER model | Sensitivity analysis: R0 = 2.7, 95% CI |
| A4 | SIR model | Sensitivity analysis: R0 = 3.1, 95% CI |
| A5 | SIR model | Sensitivity analysis: R0 = 4.3, 95% CI |
| A6 | SIR model | 95% CI, prediction cohort = 0.88, validation cohort = 0.831 |
| A7 | SVM | Accuracy = 97.5%, specificity = 99.7%, sensitivity = 95.8% |
| A8 | Machine learning models: SVM, RF, LR, and GBA models | SVM: AUC = 0.851, sensitivity = 0.677, specificity = 0.850, F1 score = 0.724, Brier score = 0.160, PPV = 0.778 |
| A9 | DT | AUC = 0.87, sensitivity = 0.807, specificity = 0.801 |
| A10 | SIR model | 95% CI, training cohort = 0.718, validation cohort = 0.70 |
| A11 | Machine learning models: SVM, RF, GBT, LR, and DT models | SVM: AUC = 0.811, sensitivity = 0.650, specificity = 0.880, F1 score = 0.714, Brier score = 0.158 |
| A12 | SIER | R0 = 7.1, prediction cohort = 0.78, testing cohort = 0.73 |
| A13 | SIER | R0 = 3.6, prediction cohort = 0.81, testing cohort = 0.78 |
| A14 | Machine learning and ensemble models: SVM, LR, RF, AdaBoost, and XGBoost | SVM: AUC = 0.80, sensitivity = 0.680, specificity = 0.890 |
| A15 | SIR model | R0 = 2.8, training cohort = 0.88, testing cohort = 0.79 |
| A16 | SIER | R0 = 2.3, 95% CI, training cohort = 0.77, testing cohort = 0.78 |
| A17 | SIR model | U.K.: R0 = 2.25, training cohort = 0.83, testing cohort = 0.78 |
| A18 | SIIR model: incorporation of I compartment for modeling asymptomatic infections | 95% CI |
| A19 | SIER | 95% CI, training cohort = 0.85, validation cohort = 0.81 |
| A20 | SIRD model | R0 = 2.3, Rt = 2.7, training cohort = 0.84, validation cohort = 0.81 |
| A21 | SIRD | R0 = 2.6, prediction cohort = 0.89, validation cohort = 0.85 |
| A22 | SIER | Rajasthan: R0 = 4.2, 95% CI |
| A23 | SIER | Maharashta: R0 = 4.3, 95% CI |
| A24 | SIER | 95% CI, training cohort = 0.714, validation cohort = 0.70 |
| A25 | SIR | 95% CI, prediction cohort = 0.651, testing cohort = 0.632 |
| A26 | SIR | 95% CI, prediction cohort = 0.68, testing cohort = 0.63 |
| A27 | SIR | 95%CI, training cohort = 0.73, testing cohort = 0.70 |
| A28 | SEIR | 95% CI |
| A29 | SEIR | Beijing: R0 = 4.5 |
| A30 | SIR model | New York: Rt = 4.4, 95% CI |
| A31 | Logistic growth curve model and time interrupted regression model | R0 = 3.8, 95% CI |
| A32 | Hybrid: SEIR and SVM | Sensitivity analysis: Italy: R0 = 4.5, 95% CI |
| A33 | Holt model, ARIMA, TBATS, and cubic smoothing spline model | ARIMA: MAPE = 5.2%, MAE = 5.3, AIC = 5.5 |
| A34 | SIR model | R0 = 2.8, 95% CI |
| A35 | SEIR | R0 = 4.3,95% CI, prediction cohort = 0.83, validation cohort = 0.81 |
| A36 | SEIR with ARIMA corrections | 95% CI, prediction cohort = 0.73, validation cohort = 0.70 |
| A37 | SIR | UIR = 20%, IFR = 0.61, TR = 0.03%, 95% CI |
| A38 | SEIR | First wave: R0 = 6.49, 95% CI |
| A39 | SEIR | R0 = 3.5, 95% CI, training cohort = 0.89, validation cohort = 0.83 |
| A40 | SIR | 95% CI, prediction cohort = 0.82, validation cohort = 0.78 |
| A41 | SQEIAR | China: prediction cohort = 0.782, validation cohort = 0.77 |
| A42 | Machine learning and regression models: SVM, DT, LR, RF, and AdaBoost | SVM: precision = 0.82, recall = 0.91, F1 score = 0.86, accuracy = 90.6% |
| A43 | SIR, RF | SIR: R0 = 3.8, 95% CI |
| A44 | SIR | 95% CI, prediction cohort = 0.86, validation cohort = 0.84 |
| A45 | Hybrid: SEIR, GBA, and linear local regression | SEIR:95% CI |
| A46 | Experimental case study | 95% CI, training cohort = 0.79, validation cohort = 0.80 |
| A47 | Case study | 95% CI, prediction cohort = 0.93, validation cohort = 0.86 |
| A48 | Experimental case study | 95% CI, training cohort = 0.718, validation cohort = 0.70 |
| A49 | Experimental case study | 95% CI, prediction cohort = 0.86, validation cohort = 0.84 |
| A50 | Bayesian model | 95% CI, AUC = 0.77, AIC = 0.73 |
Figure 12Percentage-wise disease-related parameters reported by current SLR.
Figure 13Control measures employed by the articles under study for SARS-COVID-19.
Identified key-disease related parameters and control measures for SARS-COVID-19.
| Article Id | Estimated/evaluated epidemiological parameters | Control measures incorporated |
|---|---|---|
| A1 | CFR | — |
| A2 | CFR | — |
| A3 | Reproductive rate (R0), travel considerations | — |
| A4 | Reproductive rate (R0), CFR | Quarantine |
| A5 | Reproductive rate (R0) | — |
| A6 | Infection and death rates | Lockdown |
| A7 | Infection and death rates | — |
| A8 | Infection and death rates | Testing and tracing application |
| A9 | Infection and death rates | — |
| A10 | Infection and death rates | Quarantine |
| A11 | Infection and death rates | — |
| A12 | Reproductive rate (R0), infection and death rates | Lockdown |
| A13 | Reproductive rate (R0) | — |
| A14 | Reproductive rate (R0) | — |
| A15 | Reproductive rate (R0) infection and death rates | Quarantine |
| A16 | Reproductive rate (R0) infection and death rates | Lockdown |
| A17 | Reproductive rate (R0), herd immunity | Lockdown |
| A18 | HIT | — |
| A19 | Asymptomatic infection rate | Quarantine, contact rate, lockdown |
| A20 | Infection and death rates | Quarantine and lockdown |
| A21 | CFR, reproductive rate (R0) | Quarantine |
| A22 | Contact rate, reproductive rate (R0) | Lockdown |
| A23 | Reproductive rate (R0) | Quarantine and lockdown |
| A24 | Asymptomatic infection rate, transmission rate | — |
| A25 | Transmission rate | Quarantine, social distancing |
| A26 | Infection and death rate | Contact rate |
| A27 | Transmission rate | — |
| A28 | Infection and death rate | Social distancing, undetected infection rate, testing and tracing apps |
| A29 | Reproductive rate (R0) | Quarantine |
| A30 | Infection and death rate | Lockdown, testing and tracing apps |
| A31 | Infection and death rate | Lockdown, quarantine |
| A32 | Reproductive rate (R0) | Lockdown |
| A33 | Reproductive rate (R0) | Social distancing, contact rate |
| A34 | Reproductive rate (R0) | Social distancing, contact rate |
| A35 | Reproductive rate (R0) | Quarantine, social distancing, |
| A36 | Infection and death rate | Quarantine, unidentified infection rate |
| A37 | IFR, TR | Lockdown, quarantine, undetected infection rate |
| A38 | Reproductive rate (R0), infection and death rate | — |
| A39 | Reproductive rate (R0), TSOH | Social distancing, hospitalization, quarantine, travel restrictions, contact tracing |
| A40 | Transmission rate | Quarantine, hospitalization |
| A41 | Asymptomatic infection rate | Quarantine, travel restrictions, undetected infection rate |
| A42 | Infection and death rates | Lockdown |
| A43 | Reproductive rate (R0), infection and death rates | Quarantine |
| A44 | Infection and death rates | Quarantine, lockdown |
| A45 | Infection and death rates | Quarantine |
| A46 | Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca on alpha (B.1.1.7) variant | — |
| A47 | Effect of Moderna and Pfizer-BioNTech on delta (B.1.617.2) variant | — |
| A48 | Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca on alpha (B.1.1.7) variant and delta (B.1.617.2) COVID-19 variant | — |
| A49 | Effect of Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna on delta (B.1.617.2) COVID-19 variant | — |
| A50 | Study the effect of Moderna and Oxford-AstraZeneca on infection, mortality, alpha (B.1.1.7), and delta (B.1.617.2) variant | — |
Figure 14Reported vaccine effectiveness percentage against B.1.1.7 SARS-COVID-19 variant strain.
Figure 15Reported vaccine effectiveness percentage against B.1.617.2 SARS-COVID-19 variant strain.
Figure 16Plots showing reported efficacy of different vaccines for B.1.1.7 and B.1.617.2 COVID-19 mutant strains.
Figure 17Different SARS-COVID-19 variants with their doubling time [15].
Figure 18Graph depicting reported case numbers of SARS-COVID-19 for India variants from 28 February 2020 to 30 October 2021.
Figure 19Trajectory for deaths due to the evolution of SARS-COVID-19 viral variants from 28 February 2020 to 13 December 2021.